CVS is reportedly considering spinning off its drugstore chain. The move would separate its retail pharmacies from its insurance and health services businesses. This restructuring reflects growing pressure on the company from investors and regulators.
The breakup would not silence political criticism of CVS. Lawmakers and regulators continue to scrutinize pharmacy benefit managers and vertical integration in healthcare. Splitting the company does not resolve those underlying policy concerns.
For shareholders, however, the split could unlock significant value. The drugstore business has struggled with thin margins and declining foot traffic. Separating it from the faster-growing insurance arm may create two more focused companies.
CVS acquired Aetna in 2018 for roughly $70 billion. The deal combined a retail pharmacy network with a major health insurer. Since then, the company has faced challenges integrating the two operations.
A spinoff would allow the insurance and health services side to trade at a higher multiple. Investors typically value managed care companies more favorably than retail pharmacy chains. The remaining entity would carry less debt and a cleaner growth story.
The drugstore chain would become a standalone retail business. It would need to compete with rivals like Walgreens and growing online pharmacy options. Management would face pressure to cut costs and rethink store formats.
Wall Street has shown appetite for such separations in the healthcare sector. Similar breakups have delivered strong returns for shareholders in recent years. A leaner CVS could follow that playbook if execution holds up.
